The CAR-Ms reprogrammed in situ mirrored the ACT CAR-Ms reported by Klinchinsky et al. They exerted anti-tumor activity via CAR-mediated phagocytosis, presented antigens, and activated CD8+ T cells. Here, CD8A is linked to neoplasm.